Ukraine plans to jointly manufacture lung and breast cancer drugs with Swiss pharmaceutical company Roche, Mykhailo Radutsky, chairman of the parliamentary committee on national health, medical care and medical insurance, said on his Facebook page, as part of the URC-2025 Ukraine Recovery Conference on Thursday.
“For several years, the President’s team has been negotiating with international pharmaceutical companies to localize production in Ukraine. The state enterprise “Medical Procurement of Ukraine” and Roche have signed an investment agreement to create capacities for the production of innovative drugs for lung and breast cancer in Ukraine,” he said.
Radutsky clarified that Roche will supply medicines in bulk, and their packaging, final packaging and labeling will be carried out directly in Ukraine, at the production facilities of the Ministry of Healthcare’s Medsnabzhenie branch.
He noted that in order to launch the project, it is necessary to obtain a GMP license for production and train staff.
Patients will be able to receive the first medicines under the project in 2027.
According to the State Enterprise (MoH), these are currently medicines for the two most common types of cancer – the drug for non-small cell lung cancer atezolizumab (Tecentrik) and pertuzumab + trastuzumab (Fesgo), which is used to treat breast cancer.
